Celastrol inhibits gastric cancer growth by induction of apoptosis and autophagy

BMB Reports

Volumn 47, Issue 12, 2014, Pages 697-702

  Lee, Hyun Woo ^a,b   Jang, Kenny Seung Bin ^a,c   Choi, Hye Ji ^a   Jo, Ara ^a   Cheong, Jae Ho ^a   Chun, Kyung Hee ^a  

^a Yonsei University College of Medicine   (South Korea)

^b Yonsei University   (South Korea)

^c Asia Pacific International School   (South Korea)

Author keywords

Apoptosis; Autophagy; Celastrol; Chemo therapy; Gastric cancer

Indexed keywords

MUS;

APOPTOSIS REGULATORY PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PROTEIN KINASE B; S6 KINASE; TARGET OF RAPAMYCIN KINASE; TRIPTERINE; TRITERPENE;

ANIMAL; APOPTOSIS; AUTOPHAGY; CELL MOTION; CELL PROLIFERATION; DRUG EFFECTS; G1 PHASE CELL CYCLE CHECKPOINT; HUMAN; METABOLISM; MOUSE; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TUMOR CELL LINE; XENOGRAFT;

AMP-ACTIVATED PROTEIN KINASES; ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; AUTOPHAGY; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; G1 PHASE CELL CYCLE CHECKPOINTS; HUMANS; MICE; MICE, NUDE; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RIBOSOMAL PROTEIN S6 KINASES; SIGNAL TRANSDUCTION; STOMACH NEOPLASMS; TOR SERINE-THREONINE KINASES; TRANSPLANTATION, HETEROLOGOUS; TRITERPENES;

EID: 84922272575     PISSN: 19766696     EISSN: 1976670X     Source Type: Journal    
DOI: 10.5483/BMBRep.2014.47.12.069     Document Type: Article

References (35)

1. Zagouri, F., Papadimitriou, C. A., Dimopoulos, M. A. and Pectasides, D. (2011) Molecularly targeted therapies in unresectable-metastatic gastric cancer: a systematic review. Cancer Treat. Rev. 37, 599-610.
2. Rivera, F., Vega-Villegas, M. E. and Lopez-Brea, M. F. (2007) Chemotherapy of advanced gastric cancer. Cancer Treat. Rev. 33, 315-324.
3. Wagner, A. D. and Moehler, M. (2009) Development of targeted therapies in advanced gastric cancer: promising exploratory steps in a new era. Curr. Opin. Oncol. 21, 381-385.
4. De Vita, F., Giuliani, F., Silvestris, N., Rossetti, S., Pizzolorusso, A., Santabarbara, G., Galizia, G., Colucci, G., Ciardiello, F. and Orditura, M. (2012) Current status of targeted therapies in advanced gastric cancer. Expert Opin. Ther. Targets 16, S29-34.
5. Lourenco, A. M., Ferreira, L. M. and Branco, P. S. (2012) Molecules of natural origin, semi-synthesis and synthesis with anti-inflammatory and anticancer utilities. Curr. Pharm. Des. 18, 3979-4046.
6. Shanmugam, M. K., Nguyen, A. H., Kumar, A. P., Tan, B. K. and Sethi, G. (2012) Targeted inhibition of tumor proliferation, survival, and metastasis by pentacyclic triterpenoids: potential role in prevention and therapy of cancer. Cancer Lett. 320, 158-170.
7. Setty, A. R. and Sigal, L. H. (2005) Herbal medications commonly used in the practice of rheumatology: mechanisms of action, efficacy, and side effects. Semin. Arthritis. Rheum. 34, 773-784.
8. Sassa, H., Takaishi, Y. and Terada, H. (1990) The triterpene celastrol as a very potent inhibitor of lipid peroxidation in mitochondria. Biochem. Biophys. Res. Commun. 172, 890-897.
9. He, W., Huang, F. C., Gavai, A., Chan, W. K., Amato, G., Yu, K. T. and Zilberstein, A. (1998) Novel cytokine release inhibitors. Part III: Truncated analogs of tripterine. Bioorg. Med. Chem. Lett. 8, 3659-3664.
10. Allison, A. C., Cacabelos, R., Lombardi, V. R., Alvarez, X. A. and Vigo, C. (2001) Celastrol, a potent antioxidant and anti-inflammatory drug, as a possible treatment for Alzheimer's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 25, 1341-1357.
11. Li, H., Jia, Y. F., Pan, Y., Pan, D. J., Li, D. and Zhang, L. X. (1997) Effect of tripterine on collagen-induced arthritis in rats. Zhongguo Yao Li Xue Bao. 18, 270-273.
12. Kannaiyan, R., Shanmugam, M. K. and Sethi, G. (2011) Molecular targets of celastrol derived from Thunder of God Vine: potential role in the treatment of inflammatory disorders and cancer. Cancer Lett. 303, 9-20.
13. Zhang, T., Hamza, A., Cao, X., Wang, B., Yu, S., Zhan, C. G. and Sun, D. (2008) A novel Hsp90 inhibitor to disrupt Hsp90/Cdc37 complex against pancreatic cancer cells. Mol. Cancer Ther. 7, 162-170.
14. Wang, W. B., Feng, L. X., Yue, Q. X., Wu, W. Y., Guan, S. H., Jiang, B. H., Yang, M., Liu, X. and Guo, D. A. (2012) Paraptosis accompanied by autophagy and apoptosis was induced by celastrol, a natural compound with influence on proteasome, ER stress and Hsp90. J. Cell. Physiol. 227, 2196-2206.
15. Sethi, G., Ahn, K. S., Pandey, M. K. and Aggarwal, B. B. (2007) Celastrol, a novel triterpene, potentiates TNF-induced apoptosis and suppresses invasion of tumor cells by inhibiting NF-kappaB-regulated gene products and TAK1-mediated NF-kappaB activation. Blood 109, 2727-2735.
16. Pang, X., Yi, Z., Zhang, J., Lu, B., Sung, B., Qu, W., Aggarwal, B. B. and Liu, M. (2010) Celastrol suppresses angiogenesis-mediated tumor growth through inhibition of AKT/mammalian target of rapamycin pathway. Cancer Res. 70, 1951-1959.
17. Lee, J. H., Won, Y. S., Park, K. H., Lee, M. K., Tachibana, H., Yamada, K. and Seo, K. I. (2012) Celastrol inhibits growth and induces apoptotic cell death in melanoma cells via the activation ROS-dependent mitochondrial pathway and the suppression of PI3K/AKT signaling. Apoptosis. 17, 1275-1286.
18. Zhu, H., Liu, X. W., Cai, T. Y., Cao, J., Tu, C. X., Lu, W., He, Q. J. and Yang, B. (2010) Celastrol acts as a potent antimetastatic agent targeting beta1 integrin and inhibiting cell-extracellular matrix adhesion, in part via the p38 mitogen-activated protein kinase pathway. J. Pharmacol. Exp. Ther. 334, 489-499.
19. Huang, Y., Zhou, Y., Fan, Y. and Zhou, D. (2008) Celastrol inhibits the growth of human glioma xenografts in nude mice through suppressing VEGFR expression. Cancer Lett. 264, 101-106.
20. Hansen, J., Palmfeldt, J., Vang, S., Corydon, T. J., Gregersen, N. and Bross, P. (2011) Quantitative proteomics reveals cellular targets of celastrol. PloS One 6, e26634.
21. Kannaiyan, R., Manu, K. A., Chen, L., Li, F., Rajendran, P., Subramaniam, A., Lam, P., Kumar, A. P. and Sethi, G. (2011) Celastrol inhibits tumor cell proliferation and promotes apoptosis through the activation of c-Jun N-terminal kinase and suppression of PI3 K/Akt signaling pathways. Apoptosis 16, 1028-1041.
22. Ko, A., Shin, J. Y., Seo, J., Lee, K. D., Lee, E. W., Lee, M. S., Lee, H. W., Choi, I. J., Jeong, J. S., Chun, K. H. and Song, J. (2012) Acceleration of gastric tumorigenesis through MKRN1-mediated posttranslational regulation of p14ARF. J. Natl. Cancer Inst. 104, 1660-1672.
23. Jiang, Y. and Ajani, J. A. (2010) Multidisciplinary management of gastric cancer. Curr. Opin. Gastroenterol. 26, 640-646.
24. Cervantes, A., Rosello, S., Roda, D. and Rodriguez-Braun, E. (2008) The treatment of advanced gastric cancer: current strategies and future perspectives. Ann. Oncol. 19 Suppl 5, v103-107.
25. Kim, K., Chun, K. H., Suh, P. G. and Kim, I. H. (2011) Alterations in cell proliferation related gene expressions in gastric cancer. Crit. Rev. Eukaryot. Gene Expr. 21, 237-254.
26. Chen, M., Rose, A. E., Doudican, N., Osman, I. and Orlow, S. J. (2009) Celastrol synergistically enhances temozolomide cytotoxicity in melanoma cells. Mol. Cancer Res. 7, 1946-1953.
27. Raja, S. M., Clubb, R. J., Ortega-Cava, C., Williams, S. H., Bailey, T. A., Duan, L., Zhao, X., Reddi, A. L., Nyong, A. M., Natarajan, A., Band, V. and Band, H. (2011) Anticancer activity of Celastrol in combination with ErbB2-targeted therapeutics for treatment of ErbB2-overexpressing breast cancers. Cancer Biol. Ther. 11, 263-276.
28. Sha, M., Ye, J., Zhang, L. X., Luan, Z. Y. and Chen, Y. B. (2013) Celastrol induces apoptosis of gastric cancer cells by miR-146a inhibition of NF-kappaB activity. Cancer Cell Int. 13, 50.
29. Jain, M. V., Paczulla, A. M., Klonisch, T., Dimgba, F. N., Rao, S. B., Roberg, K., Schweizer, F., Lengerke, C., Davoodpour, P., Palicharla, V. R., Maddika, S. and Los, M. (2013) Interconnections between apoptotic, autophagic and necrotic pathways: implications for cancer therapy development. J. Cell. Mol. Med. 17, 12-29.
30. Sun, H., Wang, Z. and Yakisich, J. S. (2012) Natural products targeting autophagy via the PI3K/Akt/mTOR pathway as anticancer agents. Anticancer Agents Med. Chem. 13, 1048-1056.
31. Kim, J. H., Lee, J. O., Lee, S. K., Kim, N., You, G. Y., Moon, J. W., Sha, J., Kim, S. J., Park, S. H. and Kim, H. S. (2012) Celastrol suppresses breast cancer MCF-7 cell viability via the AMP-activated protein kinase (AMPK)-induced p53-polo like kinase 2 (PLK-2) pathway. Cellular Signal. 25, 805-813.
32. Kim, S. J., Choi, I. J., Cheong, T. C., Lee, S. J., Lotan, R., Park, S. H. and Chun, K. H. (2010) Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression. Gastroenterology 138, 1035-1045.
33. Cheong, T. C., Shin, J. Y. and Chun, K. H. (2010) Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents. Cancer Sci. 101, 94-102.
34. Ahn, Y. H., Yi, H., Shin, J. Y., Lee, K. D., Shin, S. P., Lee, S. J., Song, J. and Chun, K. H. (2012) STAT3 silencing enhances the efficacy of the HSV.tk suicide gene in gastrointestinal cancer therapy. Clin. Exp. Metastasis 29, 359-369.
35. Wang, Y. G., Kim, S. J., Baek, J. H., Lee, H. W., Jeong, S. Y. and Chun, K. H. (2012) Galectin-3 increases the motility of mouse melanoma cells by regulating matrix metalloproteinase-1 expression. Exp. Mol. Med. 44, 387-393.